Developer docs
API playgroundTry for free, no card

Search company profiles

Cairo Diagnostics

Full company profile

uuid0006wxn

Namestring
Cairo Diagnostics
Legal namestring
Cairo Diagnostics, LLC
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Cairo Diagnostics is a CLIA-, CAP-, and NYSDOH-certified specialty reference laboratory headquartered in White Plains, NY, focused exclusively on hematopathology. The lab operates a multi-modality diagnostic stack spanning morphology and immunohistochemistry, 15-color flow cytometry, FISH, PCR, cytogenetics, and next-generation sequencing, supported by a clinical team of MD/PhD hematopathologists trained at MD Anderson, NYU, and Columbia and a publication record exceeding 115 peer-reviewed papers. Sub-brands include PsiGenex, a 54-gene hereditary cancer panel that extends the franchise into germline oncology testing.

The business serves community and academic hematologists, oncologists, and health systems across the New York/New Jersey/Connecticut Tri-State area, with named customers including New York-Presbyterian, White Plains Medical Group, WestMed, Crystal Run, and ProHealth. Order intake runs through online portals and bidirectional EMR integration, and the lab offers seven-days-a-week same-day STAT turnaround for time-sensitive oncology workups. Revenue mechanics follow the standard U.S. specialty reference lab model: third-party reimbursement (Medicare/Medicaid/commercial payers) per test, with consultative hematopathology services billed as professional components.

In November 2025 the company was acquired by Sonic Healthcare USA (via ProPath Services, LLC), converting Cairo from an independent regional operator into a subsidiary within one of the three largest U.S. laboratory networks. The strategic intent is to retain the hematopathology specialty franchise while leveraging Sonic's national logistics, payer contracts, and broader test menu.

Short descriptiontext

Cairo Diagnostics is a CLIA/CAP/NYSDOH-certified specialty reference lab in White Plains, NY, providing multi-modality hematopathology diagnostics — including flow cytometry, NGS, FISH, PCR, cytogenetics, and the PsiGenex hereditary cancer panel — to Tri-State hematologists, oncologists, and health systems, now operating as a Sonic Healthcare USA subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWhite Plains, United States
HQ citystring
White Plains
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hematopathology diagnostics, molecular cancer testing, flow cytometry services, cytogenetics FISH testing, hereditary cancer panels
Industry6 codes
PRIMARYHLAFAMAC
Hematology & Coagulation Laboratories
SECONDARYHLAKAFAD
Hematologic Oncology (Leukemia/Lymphoma/Myeloma)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAHAAAB
Hematology & Coagulation Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • Medical Laboratories621511
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Diagnostic Laboratory Services — Hematopathology & Molecular Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Laboratory Diagnostic Testing Services
TypeSubscription Recurring
Description

Cairo Diagnostics generates revenue through specialized hematopathology and molecular diagnostic testing services provided to referring physicians, hospitals, and academic medical centers. Services include consultation, NGS, flow cytometry, FISH, PCR, cytogenetics, and morphology/IHC testing. The company accepts all commercial insurance plans and Medicare, with a financial hardship program for uninsured or underinsured patients.

cairodiagnostics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Insurance-based laboratory testing services
ModelOtherBilling cadencePay-as-you-go
Notes

Accepts all commercial plans and Medicare. Works with insurance for in-network processing. Financial assistance available for uninsured/underinsured patients based on Federal Poverty Guidelines.

cairodiagnostics.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1PsiGenex
Description

A subsidiary brand for testing germline mutations, offering a comprehensive hereditary cancer panel that covers 54 genes associated with increased susceptibility to many cancers.

cairodiagnostics.com
Core offering1 text field

Cairo Diagnostics is a specialized hematopathology reference laboratory providing molecular profiling and diagnostic interpretation for blood cancers (leukemias, lymphomas, myelomas), bone marrow disorders, lymph node biopsies, and solid tumors. The company delivers comprehensive consults rather than raw test results, combining NGS, 15-color flow cytometry, FISH/cytogenetics, PCR, and morphology/IHC services with on-demand board-certified hematopathologist consultation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 24-48 hour FISH turnaround vs industry standard
+4 more records
Product overview1 text field

Cairo Diagnostics is a specialized hematopathology laboratory offering a comprehensive diagnostic testing portfolio focused on blood cancers and solid tumor molecular profiling. The company's offerings include consultative pathology services (primary and second opinion consultations), advanced molecular testing (NGS, solid tumor profiling, PCR), cytogenetics/FISH analysis, 15-color flow cytometry, and morphology/IHC services. The company also operates PsiGenex as a subsidiary sub-brand focused on hereditary cancer germline mutation testing. Services are designed for hematologists, oncologists, pathologists, hospitals, and academic centers, with turnaround times including same-day STAT results, 24-hour Flow Cytometry, and FISH 24/48 hour turnaround for most cases.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

One of the two largest U.S. reference laboratories, offering broad hematology, molecular, and oncology testing including NGS and flow cytometry; competes with Cairo for hospital and oncology referrals across the Tri-State.

2CBLPath
TypeDirect peer
Description

Specialty anatomic and hematopathology laboratory and historical Sonic Healthcare USA subsidiary, directly comparable to Cairo Diagnostics; several Cairo senior leaders (VP Operations, Laboratory Manager) were previously CBLPath executives.

TypeBroad incumbent
Description

Large national reference laboratory with a substantial hematology/oncology menu including molecular profiling; competes for the same hospital and community-oncology referral base, with materially greater scale and payor leverage.

TypeDirect peer
Description

Specialty oncology and hematopathology reference laboratory offering NGS, flow cytometry, FISH, and cytogenetics — directly overlapping Cairo's core service menu and target customer base of community oncologists and hospitals.

TypeDirect peer
Description

Molecular profiling laboratory offering comprehensive NGS, whole-exome, and IHC-based testing for solid and hematologic cancers; competes with Cairo in molecular oncology profiling for community oncologists.

TypeBroad incumbent
Description

Specialized molecular profiling service for solid tumors and hematologic malignancies using comprehensive NGS assays; overlaps Cairo's NGS solid-tumor and disease-focused panel offerings for oncologists seeking genomic profiling.

TypeEmerging player
Description

Genetic testing company with a hereditary cancer panel portfolio directly comparable to PsiGenex, Cairo's hereditary cancer sub-brand; overlaps in germline cancer risk assessment for high-risk patients and oncologists.

TypeEmerging player
Description

Specialized oncology genomics company focused on liquid biopsy and molecular profiling; competes for advanced molecular testing referrals in oncology, with a particularly differentiated approach to non-invasive tumor profiling.

TypeBroad incumbent
Description

Academic-affiliated national reference laboratory offering an extensive hematopathology and molecular diagnostics menu; competes for academic medical center and complex-case referrals.

TypeDirect peer
Description

Specialty hematopathology and molecular diagnostics laboratory where Cairo's Director of Sales & Marketing previously served as National Sales Manager; direct overlap in leukemia/lymphoma flow cytometry and molecular profiling services.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cairo Diagnostics

Diagnostic Laboratory Services — Hematopathology & Molecular Diagnosticscairodiagnostics.com

Cairo Diagnostics is a CLIA/CAP/NYSDOH-certified specialty reference lab in White Plains, NY, providing multi-modality hematopathology diagnostics — including flow cytometry, NGS, FISH, PCR, cytogenetics, and the PsiGenex hereditary cancer panel — to Tri-State hematologists, oncologists, and health systems, now operating as a Sonic Healthcare USA subsidiary.

What Cairo Diagnostics does

Cairo Diagnostics is a CLIA-, CAP-, and NYSDOH-certified specialty reference laboratory headquartered in White Plains, NY, focused exclusively on hematopathology. The lab operates a multi-modality diagnostic stack spanning morphology and immunohistochemistry, 15-color flow cytometry, FISH, PCR, cytogenetics, and next-generation sequencing, supported by a clinical team of MD/PhD hematopathologists trained at MD Anderson, NYU, and Columbia and a publication record exceeding 115 peer-reviewed papers. Sub-brands include PsiGenex, a 54-gene hereditary cancer panel that extends the franchise into germline oncology testing.

The business serves community and academic hematologists, oncologists, and health systems across the New York/New Jersey/Connecticut Tri-State area, with named customers including New York-Presbyterian, White Plains Medical Group, WestMed, Crystal Run, and ProHealth. Order intake runs through online portals and bidirectional EMR integration, and the lab offers seven-days-a-week same-day STAT turnaround for time-sensitive oncology workups. Revenue mechanics follow the standard U.S. specialty reference lab model: third-party reimbursement (Medicare/Medicaid/commercial payers) per test, with consultative hematopathology services billed as professional components.

In November 2025 the company was acquired by Sonic Healthcare USA (via ProPath Services, LLC), converting Cairo from an independent regional operator into a subsidiary within one of the three largest U.S. laboratory networks. The strategic intent is to retain the hematopathology specialty franchise while leveraging Sonic's national logistics, payer contracts, and broader test menu.

Cairo Diagnostics firmographics

Firmographics
Name
Cairo Diagnostics
Legal name
Cairo Diagnostics, LLC
Website
https://cairodiagnostics.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Short description
Cairo Diagnostics is a CLIA/CAP/NYSDOH-certified specialty reference lab in White Plains, NY, providing multi-modality hematopathology diagnostics — including flow cytometry, NGS, FISH, PCR, cytogenetics, and the PsiGenex hereditary cancer panel — to Tri-State hematologists, oncologists, and health systems, now operating as a Sonic Healthcare USA subsidiary.
Ownership category
akta.pro rank

Cairo Diagnostics industry classification

Industry
Product category
Diagnostic Laboratory Services — Hematopathology & Molecular Diagnostics
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAFAMAC
Hematology & Coagulation Laboratories
SECONDARYHLAKAFAD
Hematologic Oncology (Leukemia/Lymphoma/Myeloma)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAHAAAB
Hematology & Coagulation Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Hematopathology diagnostics
  • Molecular cancer testing
  • Flow cytometry services
  • Cytogenetics FISH testing
  • Hereditary cancer panels

Where Cairo Diagnostics is headquartered

Location

Headquarters

HQ city
White Plains
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cairo Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Laboratory Diagnostic Testing Services: Cairo Diagnostics generates revenue through specialized hematopathology and molecular diagnostic testing services provided to referring physicians, hospitals, and academic medical centers. Services include consultation, NGS, flow cytometry, FISH, PCR, cytogenetics, and morphology/IHC testing. The company accepts all commercial insurance plans and Medicare, with a financial hardship program for uninsured or underinsured patients.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goInsurance-based laboratory testing services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Cairo Diagnostics product offering

Product offering

Core offering

Cairo Diagnostics is a specialized hematopathology reference laboratory providing molecular profiling and diagnostic interpretation for blood cancers (leukemias, lymphomas, myelomas), bone marrow disorders, lymph node biopsies, and solid tumors. The company delivers comprehensive consults rather than raw test results, combining NGS, 15-color flow cytometry, FISH/cytogenetics, PCR, and morphology/IHC services with on-demand board-certified hematopathologist consultation.

Product overview

Cairo Diagnostics is a specialized hematopathology laboratory offering a comprehensive diagnostic testing portfolio focused on blood cancers and solid tumor molecular profiling. The company's offerings include consultative pathology services (primary and second opinion consultations), advanced molecular testing (NGS, solid tumor profiling, PCR), cytogenetics/FISH analysis, 15-color flow cytometry, and morphology/IHC services. The company also operates PsiGenex as a subsidiary sub-brand focused on hereditary cancer germline mutation testing. Services are designed for hematologists, oncologists, pathologists, hospitals, and academic centers, with turnaround times including same-day STAT results, 24-hour Flow Cytometry, and FISH 24/48 hour turnaround for most cases.

Differentiator

Problem solved

Functional benefit

Brands

  • PsiGenex: A subsidiary brand for testing germline mutations, offering a comprehensive hereditary cancer panel that covers 54 genes associated with increased susceptibility to many cancers.

Quantifiable outcome

  • 24-48 hour FISH turnaround vs industry standard
  • +4 more outcomes

Companies that use Cairo Diagnostics

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Cairo Diagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Cairo Diagnostics partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Cairo Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • Quest Diagnostics: One of the two largest U.S. reference laboratories, offering broad hematology, molecular, and oncology testing including NGS and flow cytometry; competes with Cairo for hospital and oncology referrals across the Tri-State.
  • Laboratory Corporation of America (Labcorp): Large national reference laboratory with a substantial hematology/oncology menu including molecular profiling; competes for the same hospital and community-oncology referral base, with materially greater scale and payor leverage.
  • Foundation Medicine: Specialized molecular profiling service for solid tumors and hematologic malignancies using comprehensive NGS assays; overlaps Cairo's NGS solid-tumor and disease-focused panel offerings for oncologists seeking genomic profiling.
  • ARUP Laboratories: Academic-affiliated national reference laboratory offering an extensive hematopathology and molecular diagnostics menu; competes for academic medical center and complex-case referrals.

Direct peers

  • CBLPath: Specialty anatomic and hematopathology laboratory and historical Sonic Healthcare USA subsidiary, directly comparable to Cairo Diagnostics; several Cairo senior leaders (VP Operations, Laboratory Manager) were previously CBLPath executives.
  • NeoGenomics Laboratories: Specialty oncology and hematopathology reference laboratory offering NGS, flow cytometry, FISH, and cytogenetics — directly overlapping Cairo's core service menu and target customer base of community oncologists and hospitals.
  • Caris Life Sciences: Molecular profiling laboratory offering comprehensive NGS, whole-exome, and IHC-based testing for solid and hematologic cancers; competes with Cairo in molecular oncology profiling for community oncologists.
  • siParadigm Diagnostics: Specialty hematopathology and molecular diagnostics laboratory where Cairo's Director of Sales & Marketing previously served as National Sales Manager; direct overlap in leukemia/lymphoma flow cytometry and molecular profiling services.

Emerging players

  • Invitae: Genetic testing company with a hereditary cancer panel portfolio directly comparable to PsiGenex, Cairo's hereditary cancer sub-brand; overlaps in germline cancer risk assessment for high-risk patients and oncologists.
  • Guardant Health: Specialized oncology genomics company focused on liquid biopsy and molecular profiling; competes for advanced molecular testing referrals in oncology, with a particularly differentiated approach to non-invasive tumor profiling.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cairo Diagnostics social profiles

Digital presence

Cairo Diagnostics compliance and trust

Trust signal

Compliance3 records

Cairo Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cairo Diagnostics leadership team

Management profile

Number of profiles

Profiles9 records

Cairo Diagnostics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cairo Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cairo Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cairo Diagnostics

What does Cairo Diagnostics do?

Cairo Diagnostics is a specialized hematopathology reference laboratory providing molecular profiling and diagnostic interpretation for blood cancers (leukemias, lymphomas, myelomas), bone marrow disorders, lymph node biopsies, and solid tumors. The company delivers comprehensive consults rather than raw test results, combining NGS, 15-color flow cytometry, FISH/cytogenetics, PCR, and morphology/IHC services with on-demand board-certified hematopathologist consultation.

Is Cairo Diagnostics a public or private company?

Cairo Diagnostics is a private company. It is classified as corporate owned and is currently operating.

When was Cairo Diagnostics founded?

Cairo Diagnostics was founded in 2012. It employs 51 to 100 people.

Where is Cairo Diagnostics based?

Cairo Diagnostics is headquartered in White Plains, United States, in the North America region.

How does Cairo Diagnostics make money?

One revenue line is on record: laboratory Diagnostic Testing Services.

Who are Cairo Diagnostics's main competitors?

Broad incumbents on record are Quest Diagnostics, Laboratory Corporation of America (Labcorp), Foundation Medicine and ARUP Laboratories. Direct peers are CBLPath, NeoGenomics Laboratories, Caris Life Sciences and siParadigm Diagnostics. Emerging players are Invitae and Guardant Health.

Does Cairo Diagnostics have an API?

No public API is recorded for Cairo Diagnostics.

What industry is Cairo Diagnostics in?

Cairo Diagnostics's product category is Diagnostic Laboratory Services — Hematopathology & Molecular Diagnostics. Its primary akta.pro industry code is HLAFAMAC, Hematology & Coagulation Laboratories, with a secondary code of HLAKAFAD, Hematologic Oncology (Leukemia/Lymphoma/Myeloma). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dallas InnovatesGlobal Leading Laboratory Company Makes Acquisition; Relocates to Dallas From AustinSonic Healthcare USA relocated its headquarters from Austin to Dallas in August and announced the acquisition of Cairo Diagnostics, a hematology oncology diagnostics provider serving the Connecticut, New York, and New Jersey tri-state area. The deal will enable the company to deliver comprehensive bone marrow and next-generation sequencing results in four to five days, approximately half the current turnaround time, by deploying Cairo's integrated testing technology nationwide through SHUSA's network of 45 laboratories serving over 30 million patients annually.BioSpaceSonic Healthcare USA, Inc. Announces Acquisition of Cairo Diagnostics LLC to Expand Sonic’s National Hematology Oncology Testing CapabilitiesSonic Healthcare USA, Inc. has acquired substantially all assets of Cairo Diagnostics, LLC (along with Cairo Diagnostics NJ, LLC and Rye Management and Logistics Corp.), a provider of comprehensive hematology oncology diagnostics based in White Plains, New York and Woodcliff Lake, New Jersey. The acquisition is expected to integrate Cairo's integrated testing platform—including histopathology, molecular diagnostics, cytogenetics, flow cytometry, and immunohistochemistry—into Sonic's national network, enabling in-network access for a substantial share of covered lives nationwide. The deal positions Sonic to expand into emerging oncology technologies including liquid biopsy, though financial terms were not disclosed and the transaction remains subject to customary closing conditions and regulatory approvals.G-MedtechSonic Healthcare USA Acquires Cairo Diagnostics to Expand National Oncology Testing NetworkSonic Healthcare USA acquired Cairo Diagnostics, a New York-based hematology oncology testing provider, to expand its national oncology testing network. Cairo's integrated platform combines histopathology, molecular testing, cytogenetics, flow cytometry, and immunohistochemistry, aiming to reduce delays and offer rapid results. The deal is subject to regulatory approvals, with financial terms undisclosed.Roi-njSonic Healthcare USA acquires Cairo Diagnostics to grow hematology oncology testing capabilitiesSonic Healthcare USA acquired Cairo Diagnostics, a hematology oncology diagnostics provider, on Aug. 22. Financial terms were not disclosed. Sonic plans to integrate Cairo's integrated oncology platforms into its national network, expanding access to advanced diagnostics.citybizSonic Healthcare USA Acquires Cairo DiagnosticsSonic Healthcare USA acquired substantially all of Cairo Diagnostics' assets, including its hematology oncology diagnostics labs in New York and New Jersey. The deal integrates Cairo's integrated oncology testing into Sonic's national network, with financial terms undisclosed. Cairo's capabilities will be offered in-network to a substantial share of covered lives.PR NewswireSonic Healthcare USA, Inc. Announces Acquisition of Cairo Diagnostics LLC to Expand Sonic's National Hematology Oncology Testing CapabilitiesSonic Healthcare USA acquired Cairo Diagnostics, a hematology oncology diagnostics provider, to expand its national testing capabilities. The deal integrates Cairo's integrated oncology platforms into Sonic's network, with financial terms undisclosed. The acquisition aims to offer faster, comprehensive diagnostics nationwide.GlobeNewswireEgypt Cancer Diagnostics Market Research 2023-2029: Partnerships with International Organizations Enhances Egypt's Cancer Diagnostic Services, Cairo Emerges as a Hub of Cancer DiagnosticsEgypt's cancer diagnostics market was valued at $240.67 million in 2023 and is projected to reach $352.69 million by 2029, a CAGR of 6.74%. Cairo has emerged as the country's hub for cancer diagnostics, with imaging technologies and breast cancer screening as key drivers.GlobeNewswireEgypt Diagnostic Labs Market Forecast Report to 2029, Featuring NSA Diagnostic Laboratories, Cairo Diagnostics, LifeLabs, Synlab Egypt, Alfa Labs Egypt, Al Mokhtabar Labs & Al Borg LaboratoryEgypt's diagnostic labs market was valued at $2.1 billion in 2023 and is projected to grow at a 7.51% CAGR through 2029. The report highlights Cairo as the leading region and pathology as the dominant test type, with government initiatives and POCT expansion driving demand.